CNBX (CNBX Pharmaceuticals) EPS (Basic) : $-0.02 (TTM As of Nov. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals EPS (Basic)?

CNBX Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Nov. 2024 was $-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.02.

CNBX Pharmaceuticals's EPS (Diluted) for the three months ended in Nov. 2024 was $-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Nov. 2024 was $-0.02.

CNBX Pharmaceuticals's EPS without NRI for the three months ended in Nov. 2024 was $-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Nov. 2024 was -0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

CNBX Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for CNBX Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals EPS (Basic) Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

EPS (Basic)

Get a 7-Day Free Trial

-12.00

-2.40

-3.59

-0.42

-0.02

CNBX Pharmaceuticals Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
EPS (Basic)	Get a 7-Day Free Trial															-0.01	-0.01	-	-	-

CNBX Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

CNBX Pharmaceuticals's Basic EPS for the fiscal year that ended in Aug. 2024 is calculated as

Basic EPS (A: Aug. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.695	-	0)	/	30.248
	=	-0.02

CNBX Pharmaceuticals's Basic EPS for the quarter that ended in Nov. 2024 is calculated as

Basic EPS (Q: Nov. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.034	-	0)	/	31.111
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02

CNBX Pharmaceuticals (OTCPK:CNBX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CNBX Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary